文献速递脑血管病神经重症与神经感染

脑出血的故事:从难治性疾病到可治疗疾病

The Story of Intracerebral Hemorrhage: From Recalcitrant to Treatable Disease.
PubMed 文献 · Stroke · 2021-04-08

本文基于2020年世界卒中组织/欧洲卒中组织会议的特邀报告,回顾过去35年自发性脑出血急性管理的进展。自发性脑出血是第二常见且最致命的卒中类型,目前尚无科学证实的药物或手术治疗。1990年代以来的前瞻性研究显示,多数血肿扩大发生在发病后2-3小时内,血肿扩大及脑室出血量是可改善预后的可干预因素。

要点

  • 多数自发性脑出血血肿扩大发生在发病后2-3小时内。
  • 早期强化降压试验提示收缩压目标140 mmHg,但主要终点均未阳性。
  • 止血药(去氨加压素、氨甲环酸、rFVIIa)无明确获益,血小板输注与 harm 相关。

核心结论

  • 自发性脑出血是可干预的疾病,未来治疗应聚焦于尽早给予药物和手术治疗以改善预后。

主要发现

  • 自发性脑出血是第二常见且最致命的卒中类型,无科学证实的药物或手术治疗。
  • 1990年代以来的前瞻性研究显示多数自发性脑出血血肿扩大发生在发病后2-3小时内。
  • 血肿扩大及由此产生的脑出血量和脑室出血量是可改善预后的可干预因素。
  • 聚焦早期降压的试验提示收缩压目标140 mmHg,但均未达主要终点阳性。
  • 止血药去氨加压素、氨甲环酸、rFVIIa无明确获益,血小板输注与 harm 相关;发病最初数小时内给予止血药对血肿扩大影响最大。

关键数值与推荐

  • 早期降压试验提示收缩压目标140 mmHg,但主要终点均未阳性。
  • 止血药去氨加压素、氨甲环酸、rFVIIa无明确获益,血小板输注与 harm 相关。
  • 无大型III期手术试验主要终点阳性,汇总分析提示更早清除血肿更可能获益。

临床怎么用

  • 对自发性脑出血应尽早评估并干预血肿扩大,尤其在发病后2-3小时内。
  • 早期降压可考虑收缩压目标140 mmHg,但需知悉相关试验主要终点未阳性。
  • 止血药和血小板输注不推荐常规使用,因无明确获益或与 harm 相关。
  • 手术清除血肿应尽早考虑,并强调最大化清除血肿和减少手术脑损伤。

局限性

  • 本文为特邀专题报告,非系统综述或Meta分析,未提供定量合并数据。
  • 所引试验的主要终点均未阳性,部分结论基于汇总分析而非单项大型III期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This invited special report is based on an award presentation at the World Stroke Organization/European Stroke Organization Conference in November of 2020 outlining progress in the acute management of intracerebral hemorrhage (ICH) over the past 35 years. ICH is the second most common and the deadliest type of stroke for which there is no scientifically proven medical or surgical treatment. Prospective studies from the 1990s onward have demonstrated that most growth of spontaneous ICH occurs within the first 2 to 3 hours and that growth of ICH and resulting volumes of ICH and intraventricular hemorrhage are modifiable factors that can improve outcome. Trials focusing on early treatment of elevated blood pressure have suggested a target systolic blood pressure of 140 mm Hg, but none of the trials were positive by their primary end point. Hemostatic agents to decrease bleeding in spontaneous ICH have included desmopressin, tranexamic acid, and rFVIIa (recombinant factor VIIa) without clear benefit, and platelet infusions which were associated with harm. Hemostatic agents delivered within the first several hours have the greatest impact on growth of ICH and potentially on outcome. No large Phase III surgical ICH trial has been positive by primary end point, but pooled analyses suggest that earlier ICH removal is more likely to be beneficial. Recent trials emphasize maximization of clot removal and minimizing brain injury from the surgical approach. The future of ICH therapy must focus on delivery of medical and surgical therapies as soon as possible if we are to improve outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Broderick JP, Grotta JC, Naidech AM, et al. The Story of Intracerebral Hemorrhage: From Recalcitrant to Treatable Disease. Stroke. 2021. PMID: 33827245. doi:10.1161/STROKEAHA.121.033484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。